期刊文献+

固相萃取-HPLC法同时测定盐酸帕洛诺司琼注射液中6种杂质 被引量:1

Simultaneous Determination of Six Impurities in Palonosetron Hydrochloride Injections by Solid Phase Extraction-High Performance Liquid Chromatography
下载PDF
导出
摘要 目的:固相萃取—高效液相色谱法同时测定盐酸帕洛诺司琼注射液中差向异构体、对映异构体、氮氧杂质等6种杂质的含量。方法:样品经1 mol·L^-1氢氧化钠溶液调节pH,经Agilent Bond Elut C8固相萃取柱(200 mg,3 mL)去除大部分基质干扰,实现净化与富集,再用乙醇洗脱得到富集物。采用USP40盐酸帕洛诺司琼原料药已知杂质测定方法,以Astec CHIROBIOTIC■V(250 mm × 4.6 mm,5 μm)为色谱柱对其进行分离检测。结果:6种杂质在0.2~4.3 μg·mL^-1范围内线性良好,相关系数r≥0.999 5,方法的检测限为0.056~0.065 μg·mL^-1,低、中、高3个浓度的加样回收率为90.60%~105.7%。结论:本方法可用于同时检测盐酸帕洛诺司琼注射液中的6种杂质。 Objective:To develope a simple analytical method of solid phase extraction-high performance liquid chromatography (SPE-HPLC) for the simultaneous determination of six impurities including epimer,enantiomer and N-oxide in palonosetron hydrochloride injections.Methods:The pH of the sample was adjusted by 1 mol·L^-1 sodium hydroxide,then the impurities were enriched by Agilent Bond Elut C8 solid phase extraction (200 mg,3 mL) and eluted with ethanol.The impurities were separated and detected using Astec CHIROBIOTIC■V column (250 mm × 4.6 mm,5 μm) according to the palonosetron hydrochloride monography in USP40.Result:The method showed good linear relationship (r≥0.999 5) in 0.2-4.3 μg·mL^-1 for all the analytes.The limits of detection ranged from 0.056 to 0.065 μg·mL^-1,and the recoveries of all the analytes were between 90.60%-105.7%.Conclusion:The method is suitable for the simultaneous determination of these six impurities in palonosetron hydrochloride injections.
作者 杜有国 王张权 孙平 李飞 DU Youguo;WANG Zhangquan;SUN Ping;LI Fei(Nanjing Medical University,Nanjing 211116;Jiangsu Aosaikang Pharmaceutical Co.,Ltd,Nanjing 211112)
出处 《药学与临床研究》 2019年第4期253-256,共4页 Pharmaceutical and Clinical Research
关键词 盐酸帕洛诺司琼注射液 高效液相色谱法 固相萃取法 有关物质 Palonosetron hydrochloride injection High performance liquid chromatography Solid phase extraction Related substances
  • 相关文献

参考文献7

二级参考文献26

  • 1张启明,李慧义.色谱分析中面积归一化法测定有关物质的弊与利[J].中国药品标准,2005,6(4):45-46. 被引量:14
  • 2吕庆淮,修文华,吴忠联.帕洛诺司琼的合成[J].中国新药杂志,2007,16(13):1027-1030. 被引量:1
  • 3Kowalezyk BA,Dyson NH.Hydrogenation of a chiral 1H-benz[de]isoquinolin-l-one and an equilibration usin8 palladium catalyst[J].Org Process Res Dev,1997,1 (2):117-120.
  • 4Rubenstein EB. Palonosetron:A unique 5 - HT(3) receptor antagonist indicated for the prevention of acute and delayed chemotherapy - induced nausea and vomiting. Clin Adv Hematol Oncol,2004,2 (5) : 284.
  • 5沈曦,周慧,王万青,蔡华芳.反相高效液相色谱法检测盐酸帕洛诺司琼及其有关物质[J].中国现代应用药学,2007,24(4):307-308. 被引量:4
  • 6ChP(中国药典).2005.Vol Ⅱ(二部):730
  • 7Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCI in 4 infusion solutions. Anal Pharmacother,2004,38:1608
  • 8Xu QA, Trissel LA. Stability of palonosetron hydroehloride with paclitaxel and docetaxel during simulated Y - site administration. Am J Health Syst Pharm, 2004,61 : 1596
  • 9Vajda F J, Lander C M, Hitchcock A,et, al. Changing Aus- tralian prescribing patterns for antiepilcptic drugs in pregnancy and their possible consequences [ J ]. J Clin Neurosci ,2007 ,14 ( 7 ) :611-617.
  • 10Aapro M S. Palonosetron as an anti-emetjc and anti-nau- sea agent in oneology [ J ]. Ther Clin Risk Manag, 2007, 3 (6) : 1009-1020.

共引文献12

同被引文献26

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部